Patent 7658924 was granted and assigned to Amgen on February, 2010 by the United States Patent and Trademark Office.
Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.